- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:39 | EQL PHARMA AB: Mellozzan (melatonin) has been approved in Italy | 1 | Cision News | ||
| 12.02. | EQL PHARMA AB: Nomination committee for the 2026 Annual General Meeting | 1 | Cision News | ||
| 03.02. | EQL Pharma AB: Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026 | 117 | GlobeNewswire (Europe) | Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Resolution on implementation of a long-term incentive program... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Interim Report April - December 2025 | 104 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Comments from the CEO
The third quarter... ► Artikel lesen | |
| 15.01. | Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26 | 3 | Cision News | ||
| 07.01. | Notice of extraordinary general meeting in EQL Pharma AB | 1 | Cision News | ||
| 04.12.25 | EQL Pharma AB: EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) | 301 | GlobeNewswire (Europe) | As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this... ► Artikel lesen | |
| 03.12.25 | EQL Pharma AB: EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO) | 139 | GlobeNewswire (Europe) | EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting.... ► Artikel lesen | |
| EQL PHARMA Aktie jetzt für 0€ handeln | |||||
| 17.11.25 | EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm | 13 | Cision News | ||
| 14.11.25 | EQL Pharma AB: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany | 634 | GlobeNewswire (Europe) | EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL... ► Artikel lesen | |
| 05.11.25 | EQL Pharma AB: Interim Report April - September 2025 | 152 | GlobeNewswire (Europe) | A tough quarter for EQL
Comments from the CEO
The second quarter of 2025/26 was marked by unforeseen delivery disruptions, resulting in sales growth of only 1%. The EBITDA margin, which was naturally... ► Artikel lesen | |
| 22.10.25 | Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26 | 3 | Cision News | ||
| 06.10.25 | EQL Pharma AB: EQL Pharma in process of recruiting new Chief Commercial Officer (CCO) | 161 | GlobeNewswire (Europe) | EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position.... ► Artikel lesen | |
| 30.09.25 | Change in number of shares and votes in EQL Pharma AB | 1 | Cision News | ||
| 22.09.25 | EQL Pharma AB: Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected | 294 | GlobeNewswire (Europe) | EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made... ► Artikel lesen | |
| 25.08.25 | EQL Pharma AB: EQL Pharma's Chief Commercial Officer (CCO) sells shares to buy apartment for daughter | 209 | GlobeNewswire (Europe) | EQL Pharma's Chief Commercial Officer (CCO) Alexander Brising has recently sold shares for approximately SEK 2.1 million to pay for an apartment for his daughter who is starting university. "Not a decision... ► Artikel lesen | |
| 21.08.25 | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 21 August 2025 | 224 | GlobeNewswire (Europe) | Today, on 21 August 2025, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
| 08.08.25 | EQL Pharma AB: Interim Report April - June 2025 | 425 | GlobeNewswire (Europe) | A strong start to the year - Sales and operating profit growing, good progress in business development
April - June 2025
Consolidated sales during the first quarter, April to June amounted to SEK... ► Artikel lesen | |
| 08.07.25 | EQL Pharma AB: EQL takes first step to establish itself in Germany and the Netherlands | 172 | GlobeNewswire (Europe) | EQL has now taken the first step to establish itself in Germany and the Netherlands by recruiting key people with knowledge of the local markets who can identify, develop/in-license and launch niche... ► Artikel lesen | |
| 02.07.25 | EQL Pharma AB: Memprex© (methenamine hippurate) license signed with partner for BeNeLux | 403 | GlobeNewswire (Europe) | EQL's key product Memprex© has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV, a leading local pharmaceutical company specialising in women's health... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 388,65 | -0,49 % | VERTEX PHARMACEUTICALS INC in ruhiger Marktstruktur | ||
| UNITED THERAPEUTICS | 461,70 | +0,54 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,460 | -2,26 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| INDIVIOR PHARMACEUTICALS | 24,400 | -0,81 % | Indivior Pharmaceuticals Inc.: Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results | Generated Record Quarterly and Full-Year Total SUBLOCADE Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly... ► Artikel lesen | |
| CAMURUS | 41,740 | +2,00 % | Camurus AB: Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer | Lund, Sweden - 17 February 2026 - Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus' Chief Corporate Development Officer (CCDO) and member of the executive... ► Artikel lesen | |
| BAYER | 38,330 | +1,56 % | Streit mit Bayer beigelegt: Formycon sichert Vermarktungsstart für Aflibercept-Biosimilar FYB203 in Europa+ | Die Vereinbarung ermögliche Formycon die Markteinführung von FYB203 in Europa und wichtigen anderen Schlüsselmärkten ab Mai. Die Formycon AG habe gemeinsam mit ihrem Lizenzpartner Klinge Biopharma eine... ► Artikel lesen | |
| MERCK KGAA | 105,90 | +2,47 % | EQS-DD: Merck KGaA: Belén Garijo Lopez, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.03.2026 / 10:59... ► Artikel lesen | |
| NOVO NORDISK | 31,855 | -0,28 % | Eli Lilly: Analyst warnt - auch Novo Nordisk fällt | Kräftig nach unten ging es am Dienstag bei der Aktie von Eli Lilly. Mit einem Minus von fast sechs Prozent gehörte das Papier zu den stärksten Verlierern des Tages im S&P 500. Auch die Aktie von Novo... ► Artikel lesen | |
| GSK | 23,430 | +2,72 % | FDA genehmigt Lynavoy von GSK zur Behandlung von Juckreiz bei PBC | Der britische Pharmakonzern GSK plc hat die Zulassung seines Medikaments Lynavoy in den USA erhalten. Die US-Arzneimittelbehörde U.S. Food and Drug Administration genehmigte das Präparat zur Behandlung... ► Artikel lesen | |
| DERMAPHARM | 42,550 | +1,79 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| PFIZER | 23,350 | +0,30 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| ASTRAZENECA | 161,45 | +0,65 % | Hacker stehlen AstraZeneca-Quellcode | ||
| SANOFI | 79,35 | +1,87 % | BERENBERG stuft SANOFI auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Sanofi mit einem Kursziel von 105 Euro auf "Buy" belassen. Die Zurückhaltung der Anleger vor der Strategievorstellung des neuen Chefs bremse... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 22,970 | 0,00 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| PMGC | 2,880 | 0,00 % | Morning Market Movers: PMGC Holdings, urban-gro, PTL Limited, Ridgetech See Big Swings | BEIJING (dpa-AFX) - At 8:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
EQL PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +3,12 % bei einem Aktienkurs von 4,785 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EQL PHARMA AB finden Sie auf Wallstreet Online.